

2020/21 Month 11 Financial Performance

Author: Tarun Basra - Head of Financial Performance

Sponsor: Simon Lazarus - Chief Financial Officer

Trust Board paper F5

Purpose of Report:

This paper is for:	Description	Select (X)
Decision	To formally receive a report and approve its recommendations OR a particular course of action	
Discussion	To discuss, in depth, a report noting its implications without formally approving a recommendation or action	X
Assurance	To assure the Board that systems and processes are in place, or to advise a gap along with treatment plan	
Noting	For noting without the need for discussion	

Previous Consideration:

Meeting	Date	Please clarify the purpose of the paper to that meeting using the categories above
CMG Board (specify which CMG)		
FRB	17.03.21	Discussion
FIC	25.03.21	Discussion
Trust Board		

Executive Summary

Context:

This paper updates the Trust Board on the financial performance of the Trust at Month 11 of 2020/21.

To support the Trust during Covid-19, NHSE&I are providing an upfront Top Up payment. This was estimated from the Trust's underlying financial position.

Questions:

1. What is the financial performance for the period ending 28th February 2021?

The actual financial position including Top Up funding is a £35.7m surplus, which is £0.9m favourable to forecast.

2. What are the main issues of note in the Month 7-11 financial performance?

The main issues are as follows:

- Lower pay expenditure than forecast of £0.7m, reflecting lower expenditure on baseline costs
- Lower non pay expenditure than forecast of £2.3m, reflecting lower expenditure on Covid-19 (£0.3m) and baseline costs (£1.9m)
- Lower income than forecast of £1.6m, reflecting adjustments to the partially completed spells and maternity pathway provisions

3. What are the risks to financial performance in the remainder of the year?

- The Trust is currently forecasting an income and expenditure surplus at 31st March 2021 of £26.9m. This reflects provisions of £7m relating to the review of the 2019/20 Accounts, and £5m for 2020/21, which are subject to confirmation

Input Sought:

The Trust Board is asked to **note**:

- The Month 11 (2020/21) reported financial position
- The year end forecast outturn

For Reference:

This report relates to the following UHL quality and supporting priorities:

1. Quality priorities

Safe, surgery and procedures	[Yes /No /Not applicable]
Improved Cancer pathways	[Yes /No /Not applicable]
Streamlined emergency care	[Yes /No /Not applicable]
Better care pathways	[Yes /No /Not applicable]
Ward accreditation	[Yes /No /Not applicable]

2. Supporting priorities:

People strategy implementation	[Yes /No /Not applicable]
Investment in sustainable Estate and reconfiguration	[Yes /No /Not applicable]
e-Hospital	[Yes /No /Not applicable]
Embedded research, training and education	[Yes /No /Not applicable]
Embed innovation in recovery and renewal	[Yes /No /Not applicable]
Sustainable finances	[Yes] /No /Not applicable]

3. Equality Impact Assessment and Patient and Public Involvement considerations

- What was the outcome of your Equality Impact Assessment (EIA)? **Not applicable**
- Briefly describe the Patient and Public Involvement (PPI) activities undertaken in relation to this report, or confirm that none were required. **None required**
- How did the outcome of the EIA influence your Patient and Public Involvement? **Not applicable**
- If an EIA was not carried out, what was the rationale for this decision? **Not applicable**

4. Risk and Assurance**Risk Reference:**

Does this paper reference a risk event?	Select (X)	Risk Description:
Strategic: Does this link to a <i>Principal Risk</i> on the BAF?	X	Principal Risk 4 – Financial Sustainability
Organisational: Does this link to an <i>Operational/Corporate Risk</i> on Datix Register		
New Risk identified in paper: What <i>type</i> and <i>description</i> ?		
None		

5. Scheduled date for the **next paper** on this topic: 3 June 2021
6. Executive Summaries should not exceed **5 sides** [My paper does/~~does not~~ comply]



NHS

**University Hospitals
of Leicester**

NHS Trust

Caring at its best

Financial Performance Report

February 2021

One team shared values



Exec summary

Caring at its best

- The Trust has reported a YTD surplus of £35.7m. The YTD month 11 position is £0.9m favourable to the forecast (Page 5 breaks this down by category of expenditure).
- After potential provisions of c£12m (including c£7m relating to the review of the 2019/20 Accounts) which are being validated, the Trust is currently forecasting a £26.9m surplus at 31st March 2021. The final reported position for 2020/21 is contingent on the outcome of the review of the 2019/20 Accounts and confirmed financial impact on 2020/21, and actual approved 2020/21 provisions. It is anticipated that the Trust's operational expenditure position in March 2021 will be consistent with current expenditure trends.
- The driver for this financial improvement is lower recruitment levels than planned, reduced restoration and recovery activity, reduced winter fill due to staff shortages, increased income from Heath Education England, and significant underspends in non-pay as a result of reduced activity (Page 10 shows the detail by category).
- The Trust has reported a risk adjusted YTD CIP cash releasing position of £7.2m. The end of year forecast projection for non risk adjusted cash releasing CIP for months 7-12 is £9.3m (Page 12-13 details CIP delivery).

Key highlights (1/2)

Forecast


- The forecast reflects CMG and Directorate forecast outturns at month 11. The detail broken down by category is shown on page 10.
- CMGs have forecasted the ongoing impact of Covid-19 on restoration and recovery, non recurrent year end consumable spend and reduced elective activity, with an assumed increase in activity and expenditure in March.
- A £7m forecast provision has been included to reflect the risk of the 2019/20 accounts audit.
- Additional provisions totalling £5m are included, which are subject to validation by the Senior Finance Team.
- It has been confirmed that national funding is to be provided for the increase in annual leave provision required and accrual required relating to the Flowers legal case.
- The impact of the Covid-19 vaccination programme has been included into the forecast and that additional expenditure incurred will be fully funded.

Cash flow & Underlying Cash Position vs Operating Deficit


- The Trust's cash position at the end of month 11 was £145.5m. After adjusting for SLA payments received in advance, the Trust's underlying cash position is c£54m. Capital payments will also further accelerate in March, as well as settlement of the bi-annual PDC dividend charge (£10.8m), resulting in further cash reductions.

Key highlights (2/2)


Pay Run Rate




Agency Run Rate




Plan vs Actual - Substantive Pay Spend




Plan vs Actual - Agency Pay Spend



WLIs – Restoration and Recovery



WTE Run Rate as per CMGs



	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar-21
Covid-19	72.61	107.51	135.82	159.47	187.68	206.38
Restoration and recovery	35.89	26.66	33.25	22.24	23.19	39.64
Winter	6.61	48.58	77.58	82.19	144.88	142.67
CIP	-7.30	-7.30	-10.88	-9.47	-10.15	-8.50

Summary financial position (M7-M12)

	In month			YTD			FOT		
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000	£000	£000	£000
Patient care income	79,326	77,826	(1,500)	398,703	397,203	(1,500)	469,879	475,614	5,735
Other income	25,765	25,657	(108)	129,403	129,296	(108)	160,813	159,638	(1,175)
Total income	105,091	103,484	(1,607)	528,106	526,499	(1,607)	630,692	635,252	4,560
Pay costs	(61,141)	(60,478)	663	(303,735)	(303,072)	663	(365,352)	(366,136)	(784)
Non-pay costs	(33,415)	(31,162)	2,253	(164,764)	(162,511)	2,253	(215,194)	(210,003)	5,192
Total costs	(94,556)	(91,640)	2,916	(468,499)	(465,584)	2,916	(580,546)	(576,139)	4,407
EBITDA	10,535	11,844	1,308	59,607	60,915	1,308	50,146	59,113	8,967
Non-operating costs	(3,740)	(3,649)	91	(22,089)	(21,999)	91	(25,830)	(27,379)	(1,549)
Retained surplus / (deficit)	6,796	8,194	1,399	37,517	38,916	1,399	24,316	31,734	7,418
Donated assets	77	(446)	(523)	(2,708)	(3,231)	(523)	(6,120)	(4,790)	1,330
Net surplus / (deficit)	6,873	7,748	876	34,810	35,685	876	18,196	26,944	8,747
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus/(deficit) against control total	6,873	7,748	876	34,810	35,685	876	18,196	26,944	8,747

Main areas of variance:

- **Patient Care Income (PCI):** Primarily relating to Excluded Drugs and Devices performance in relation to specialised drugs and the partially completed spells/maternity pathway provision.
- **Total Pay Costs:** Reflecting lower recruitment levels than planned, reduced restoration and recovery activity and the reduced winter fill due to staff shortages.
- **Non-Pay:** The favourable variance against forecast is due to significant underspends as a result of reduced elective activity.

Appendix 1: total 2020/21 forecast (M7-M12)

	Actual	Actual	Actual	Actual	Actual	Forecast	Forecast	In month			YTD			FOT		
	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar-21	Full year	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000	£000
Patient care income	80,313	80,160	78,887	80,018	77,826	78,411	475,614	79,326	77,826	(1,500)	398,703	397,203	(1,500)	469,879	475,614	5,735
Other income	22,967	28,804	25,746	26,121	25,657	30,342	159,638	25,765	25,657	(108)	129,403	129,296	(108)	160,813	159,638	(1,175)
Total income	103,280	108,964	104,632	106,139	103,484	108,753	635,252	105,091	103,484	(1,607)	528,106	526,499	(1,607)	630,692	635,252	4,560
Pay costs	(60,748)	(59,981)	(61,647)	(60,218)	(60,478)	(63,064)	(366,136)	(61,141)	(60,478)	663	(303,735)	(303,072)	663	(365,352)	(366,136)	(784)
Non-pay costs	(35,453)	(35,376)	(31,620)	(28,901)	(31,162)	(47,491)	(210,003)	(33,415)	(31,162)	2,253	(164,764)	(162,511)	2,253	(215,194)	(210,003)	5,192
Total costs	(96,201)	(95,356)	(93,267)	(89,120)	(91,640)	(110,555)	(576,139)	(94,556)	(91,640)	2,916	(468,499)	(465,584)	2,916	(580,546)	(576,139)	4,407
EBITDA	7,079	13,608	11,365	17,019	11,844	(1,802)	59,113	10,535	11,844	1,308	59,607	60,915	1,308	50,146	59,113	8,967
Non-operating costs	(4,740)	(3,629)	(3,458)	(6,522)	(3,649)	(5,380)	(27,379)	(3,740)	(3,649)	91	(22,089)	(21,999)	91	(25,830)	(27,379)	(1,549)
Retained surplus / (deficit)	2,339	9,978	7,907	10,497	8,194	(7,182)	31,734	6,796	8,194	1,399	37,517	38,916	1,399	24,316	31,734	7,418
Donated assets	66	(2,593)	50	(308)	(446)	(1,559)	(4,790)	77	(446)	(523)	(2,708)	(3,231)	(523)	(6,120)	(4,790)	1,330
Net surplus / (deficit)	2,405	7,385	7,957	10,189	7,748	(8,741)	26,944	6,873	7,748	876	34,810	35,685	876	18,196	26,944	8,747
Provider sustainability fund	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surplus/(deficit) against control total	2,405	7,385	7,957	10,189	7,748	(8,741)	26,944	6,873	7,748	876	34,810	35,685	876	18,196	26,944	8,747

The points below summarise the key movement in the forecast surplus at month 10 of £18.2m, to the revised month 11 surplus of £26.9m:

- An increase in patient care income of £5.9m, reflecting income offsetting the partially completed spells and the maternity pathway adjustments
- An improvement in CMG expenditure of £3.1m, reflecting assumptions of continued reduced activity as seen in January and February 2021.
- A reduction of c£0.3m expenditure relating to non-recurrent expenditure. The total provision at month 10 was £3m and CMGs have updated forecasts to reflect an estimated spend of c£2.7m.

Appendix 2: break down of total forecast (1/3)

	In month			YTD			FOT		
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000	£000	£000	£000
Baseline forecast									
Patient care income	79,326	77,826	(1,500)	398,703	397,203	(1,500)	469,879	475,614	5,735
Other income	21,054	21,375	321	108,347	108,669	321	135,251	134,484	(767)
Total income	100,380	99,202	(1,178)	507,050	505,872	(1,178)	605,130	610,098	4,967
Pay costs	(60,246)	(59,554)	692	(300,577)	(299,885)	692	(361,199)	(362,058)	(859)
Non pay costs	(32,471)	(31,094)	1,377	(161,964)	(160,587)	1,377	(209,508)	(206,636)	2,872
Total costs	(92,716)	(90,648)	2,068	(462,541)	(460,472)	2,068	(570,707)	(568,694)	2,013
EBITDA	7,664	8,554	890	44,509	45,400	890	34,424	41,404	6,980
Non-operating costs	(3,740)	(3,649)	91	(22,089)	(21,999)	91	(25,830)	(27,379)	(1,549)
Retained surplus / (deficit)	3,924	4,905	981	22,420	23,401	981	8,594	14,024	5,430
Donated assets	77	(446)	(523)	(2,708)	(3,231)	(523)	(6,120)	(4,790)	1,330
Net deficit	4,001	4,459	457	19,713	20,170	457	2,474	9,234	6,760
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus / (deficit) against control total	4,001	4,459	457	19,713	20,170	457	2,474	9,234	6,760
COVID									
Patient care income	0	0	0	0	0	0	0	0	0
Other income	4,643	4,117	(527)	20,474	19,947	(527)	24,913	24,404	(508)
Total income	4,643	4,117	(527)	20,474	19,947	(527)	24,913	24,404	(508)
Pay costs	(1,068)	(1,049)	19	(3,329)	(3,310)	19	(4,302)	(4,231)	71
Non pay costs	(1,070)	(762)	308	(3,374)	(3,066)	308	(6,366)	(4,459)	1,907
Total costs	(2,138)	(1,811)	327	(6,704)	(6,376)	327	(10,668)	(8,690)	1,978
EBITDA	2,505	2,305	(199)	13,771	13,571	(199)	14,245	15,715	1,470
Non-operating costs	0	0	0	0	0	0	0	0	0
Retained surplus / (deficit)	2,505	2,305	(199)	13,771	13,571	(199)	14,245	15,715	1,470
Donated assets	0	0	0	0	0	0	0	0	0
Net deficit	2,505	2,305	(199)	13,771	13,571	(199)	14,245	15,715	1,470
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus / (deficit) against control total	2,505	2,305	(199)	13,771	13,571	(199)	14,245	15,715	1,470

Appendix 2: break down of total forecast (2/3)

	In month			YTD			FOT		
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000	£000	£000	£000
Restoration and recovery									
Patient care income	0	0	0	0	0	0	0	0	0
Other income	0	0	0	0	0	0	0	0	0
Total income	0	0	0	0	0	0	0	0	0
Pay costs	(171)	(142)	28	(1,413)	(1,384)	28	(1,753)	(1,648)	105
Non pay costs	(423)	(443)	(20)	(2,215)	(2,235)	(20)	(2,833)	(2,804)	29
Total costs	(594)	(585)	8	(3,628)	(3,620)	8	(4,586)	(4,452)	134
EBITDA	(594)	(585)	8	(3,628)	(3,620)	8	(4,586)	(4,452)	134
Non-operating costs	0	0	0	0	0	0	0	0	0
Retained surplus / (deficit)	(594)	(585)	8	(3,628)	(3,620)	8	(4,586)	(4,452)	134
Donated assets	0	0	0	0	0	0	0	0	0
Net deficit	(594)	(585)	8	(3,628)	(3,620)	8	(4,586)	(4,452)	134
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus / (deficit) against control total	(594)	(585)	8	(3,628)	(3,620)	8	(4,586)	(4,452)	134
Winter pressures									
Patient care income	0	0	0	0	0	0	0	0	0
Other income	0	0	0	0	0	0	0	0	0
Total income	0	0	0	0	0	0	0	0	0
Pay costs	(341)	(381)	(40)	(1,237)	(1,277)	(40)	(1,574)	(1,669)	(96)
Non pay costs	(58)	(28)	30	(346)	(316)	30	(372)	(361)	11
Total costs	(399)	(409)	(10)	(1,583)	(1,593)	(10)	(1,946)	(2,030)	(84)
EBITDA	(399)	(409)	(10)	(1,583)	(1,593)	(10)	(1,946)	(2,030)	(84)
Non-operating costs	0	0	0	0	0	0	0	0	0
Retained surplus / (deficit)	(399)	(409)	(10)	(1,583)	(1,593)	(10)	(1,946)	(2,030)	(84)
Donated assets	0	0	0	0	0	0	0	0	0
Net deficit	(399)	(409)	(10)	(1,583)	(1,593)	(10)	(1,946)	(2,030)	(84)
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus / (deficit) against control total	(399)	(409)	(10)	(1,583)	(1,593)	(10)	(1,946)	(2,030)	(84)

Appendix 2: break down of total forecast (3/3)

	In month			YTD			FOT		
	Forecast	Actual	Variance	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000	£000	£000	£000
CIP savings									
Patient care income	0	0	0	0	0	0	0	0	0
Other income	67	165	98	582	679	98	649	750	101
Total income	67	165	98	582	679	98	649	750	101
Pay costs	685	648	(38)	2,821	2,784	(38)	3,474	3,469	(5)
Non pay costs	607	1,166	559	3,135	3,694	559	3,886	4,258	372
Total costs	1,292	1,813	521	5,956	6,477	521	7,360	7,727	367
EBITDA	1,360	1,979	619	6,538	7,157	619	8,009	8,477	467
Non-operating costs	0	0	0	0	0	0	0	0	0
Retained surplus / (deficit)	1,360	1,979	619	6,538	7,157	619	8,009	8,477	467
Donated assets	0	0	0	0	0	0	0	0	0
Net deficit	1,360	1,979	619	6,538	7,157	619	8,009	8,477	467
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus / (deficit) against control total	1,360	1,979	619	6,538	7,157	619	8,009	8,477	467
Total forecast									
Patient Care Income	79,326	77,826	(1,500)	398,703	397,203	(1,500)	469,879	475,614	5,735
Other Income	25,765	25,657	(108)	129,403	129,296	(108)	160,813	159,638	(1,175)
Total Income	105,091	103,484	(1,607)	528,106	526,499	(1,607)	630,692	635,252	4,560
Pay costs	(61,141)	(60,478)	663	(303,735)	(303,072)	663	(365,352)	(366,136)	(784)
Non pay costs	(33,415)	(31,162)	2,253	(164,764)	(162,511)	2,253	(215,194)	(210,003)	5,192
Total costs	(94,556)	(91,640)	2,916	(468,499)	(465,584)	2,916	(580,546)	(576,139)	4,407
EBITDA	10,535	11,844	1,308	59,607	60,915	1,308	50,146	59,113	8,967
Non-operating costs	(3,740)	(3,649)	91	(22,089)	(21,999)	91	(25,830)	(27,379)	(1,549)
Retained surplus / (deficit)	6,796	8,194	1,399	37,517	38,916	1,399	24,316	31,734	7,418
Donated assets	77	(446)	(523)	(2,708)	(3,231)	(523)	(6,120)	(4,790)	1,330
Net deficit	6,873	7,748	876	34,810	35,685	876	18,196	26,944	8,747
Provider sustainability fund	0	0	0	0	0	0	0	0	0
Surplus / (deficit) against control total	6,873	7,748	876	34,810	35,685	876	18,196	26,944	8,747

Appendix 3 – forecast outturn analysis

	M7-M12 Forecast @ M10 £'000							M7-12 Actuals/FOT @ M11 £'000							M7-M12 - Actuals/FOT Variance @ M11 £'000						
	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
	NHS Patient Income	0	0	0	0	0	469,879	469,879	0	0	0	0	0	475,614	475,614	0	0	0	0	0	5,735
Other Operating Income	24,913	0	0	228	421	135,251	160,813	24,404	0	0	236	514	134,484	159,638	(508)	0	0	8	92	(767)	(1,175)
Total Income	24,913	0	0	228	421	605,130	630,692	24,404	0	0	236	514	610,098	635,252	(508)	0	0	8	92	4,967	4,560
Non Agency Pay	(3,218)	(1,460)	(1,012)	897	2,176	(351,420)	(354,038)	(3,201)	(1,334)	(1,157)	894	2,202	(352,596)	(355,191)	17	126	(145)	(2)	26	(1,175)	(1,153)
Agency Pay	(1,083)	(293)	(562)	363	38	(9,778)	(11,314)	(1,029)	(313)	(512)	334	38	(9,462)	(10,945)	54	(21)	49	(29)	0	316	369
Non-pay	(6,366)	(2,833)	(372)	2,422	1,464	(209,508)	(215,194)	(4,459)	(2,804)	(361)	2,343	1,914	(206,636)	(210,003)	1,907	29	11	(79)	451	2,872	5,192
Total Operating Costs	(10,668)	(4,586)	(1,946)	3,682	3,678	(570,707)	(580,546)	(8,690)	(4,452)	(2,030)	3,572	4,155	(568,694)	(576,139)	1,978	134	(84)	(110)	477	2,013	4,407
EBITDA	14,245	(4,586)	(1,946)	3,910	4,099	34,424	50,146	15,715	(4,452)	(2,030)	3,808	4,669	41,404	59,113	1,470	134	(84)	(102)	570	6,980	8,967
Non Operating Costs	0	0	0	0	0	(25,830)	(25,830)	0	0	0	0	0	(27,379)	(27,379)	0	0	0	0	0	(1,549)	(1,549)
Retained Surplus/(Deficit)	14,245	(4,586)	(1,946)	3,910	4,099	8,594	24,316	15,715	(4,452)	(2,030)	3,808	4,669	14,024	31,734	1,470	134	(84)	(102)	570	5,430	7,418
Donated Assets	0	0	0	0	0	(6,120)	(6,120)	0	0	0	0	0	(4,790)	(4,790)	0	0	0	0	0	1,330	1,330
Net Surplus/(Deficit)	14,245	(4,586)	(1,946)	3,910	4,099	2,474	18,196	15,715	(4,452)	(2,030)	3,808	4,669	9,234	26,944	1,470	134	(84)	(102)	570	6,760	8,747

	M11 YTD Forecast @ M10 £'000							YTD Actuals/FOT @ M11 £'000							YTD - Actuals/FOT @ M11 Variance £'000						
	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
	NHS Patient Income	0	0	0	0	0	398,703	398,703	0	0	0	0	0	397,203	397,203	0	0	0	0	0	(1,500)
Other Operating Income	20,474	0	0	208	374	108,347	129,403	19,947	0	0	213	467	108,669	129,296	(527)	0	0	5	92	321	(108)
Total Income	20,474	0	0	208	374	507,050	528,106	19,947	0	0	213	467	505,872	526,499	(527)	0	0	5	92	(1,178)	(1,607)
Non Agency Pay	(2,495)	(1,185)	(807)	751	1,750	(292,493)	(294,480)	(2,493)	(1,136)	(896)	753	1,740	(292,069)	(294,102)	1	49	(89)	2	(10)	424	378
Agency Pay	(835)	(228)	(430)	283	38	(8,084)	(9,255)	(817)	(248)	(381)	253	38	(7,816)	(8,970)	18	(21)	49	(29)	0	268	285
Non-pay	(3,374)	(2,215)	(346)	1,949	1,186	(161,964)	(164,764)	(3,066)	(2,235)	(316)	2,040	1,654	(160,587)	(162,511)	308	(20)	30	91	468	1,377	2,253
Total Operating Costs	(6,704)	(3,628)	(1,583)	2,982	2,974	(462,541)	(468,499)	(6,376)	(3,620)	(1,593)	3,046	3,431	(460,472)	(465,584)	327	8	(10)	64	457	2,068	2,916
EBITDA	13,771	(3,628)	(1,583)	3,190	3,348	44,509	59,607	13,571	(3,620)	(1,593)	3,259	3,898	45,400	60,915	(199)	8	(10)	69	550	890	1,308
Non Operating Costs	0	0	0	0	0	(22,089)	(22,089)	0	0	0	0	0	(21,999)	(21,999)	0	0	0	0	0	91	91
Retained Surplus/(Deficit)	13,771	(3,628)	(1,583)	3,190	3,348	22,420	37,517	13,571	(3,620)	(1,593)	3,259	3,898	23,401	38,916	(199)	8	(10)	69	550	981	1,399
Donated Assets	0	0	0	0	0	(2,708)	(2,708)	0	0	0	0	0	(3,231)	(3,231)	0	0	0	0	0	(523)	(523)
Net Surplus/(Deficit)	13,771	(3,628)	(1,583)	3,190	3,348	19,713	34,810	13,571	(3,620)	(1,593)	3,259	3,898	20,170	35,685	(199)	8	(10)	69	550	457	876

	M11 Forecast @ M10 £'000							M11 Actuals £'000							M11 FOT Variance £'000						
	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP	CIP Non Rec	Baseline	Total	Covid	R&R	Winter	CIP Rec	CIP Non Rec	Baseline	Total
	NHS Patient Income	0	0	0	0	0	79,326	79,326	0	0	0	0	0	77,826	77,826	0	0	0	0	0	(1,500)
Other Operating Income	4,643	0	0	20	47	21,054	25,765	4,117	0	0	25	140	21,375	25,657	(527)	0	0	5	92	321	(108)
Total Income	4,643	0	0	20	47	100,380	105,091	4,117	0	0	25	140	99,202	103,484	(527)	0	0	5	92	(1,178)	(1,607)
Non Agency Pay	(820)	(116)	(210)	146	443	(58,559)	(59,115)	(818)	(66)	(299)	148	433	(58,135)	(58,738)	1	49	(89)	2	(10)	424	378
Agency Pay	(248)	(55)	(132)	96	0	(1,687)	(2,026)	(231)	(76)	(82)	67	0	(1,419)	(1,741)	18	(21)	49	(29)	0	268	285
Non-pay	(1,070)	(423)	(58)	411	195	(32,471)	(33,415)	(762)	(443)	(28)	502	663	(31,094)	(31,162)	308	(20)	30	91	468	1,377	2,253
Total Operating Costs	(2,138)	(594)	(399)	654	638	(92,716)	(94,556)	(1,811)	(585)	(409)	718	1,096	(90,648)	(91,640)	327	8	(10)	64	457	2,068	2,916
EBITDA	2,505	(594)	(399)	674	686	7,664	10,535	2,305	(585)	(409)	743	1,236	8,554	11,844	(199)	8	(10)	69	550	890	1,308
Non Operating Costs	0	0	0	0	0	(3,740)	(3,740)	0	0	0	0	0	(3,649)	(3,649)	0	0	0	0	0	91	91
Retained Surplus/(Deficit)	2,505	(594)	(399)	674	686	3,924	6,796	2,305	(585)	(409)	743	1,236	4,905	8,194	(199)	8	(10)	69	550	981	1,399
Donated Assets	0	0	0	0	0	77	77	0	0	0	0	0	(446)	(446)	0	0	0	0	0	(523)	(523)
Net Surplus/(Deficit)	2,505	(594)	(399)	674	686	4,001	6,873	2,305	(585)	(409)	743	1,236	4,459	7,748	(199)	8	(10)	69	550	457	876

Appendix 4: WTE, pay and WLI breakdown

	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Actual	Forecast	In month		
	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar-21	Forecast M11	Actual M11	Variance
Baseline forecast															
Substantive	13921	13948	13881	13865	13908	13847	13831	13816	13861	13840	13955	13964	13865	13955	90
Bank	564	504	513	634	712	710	748	646	590	573	600	602	563	600	37
Agency	225	232	298	144	309	307	312	329	303	340	348	359	342	348	5
Sub-total	14710	14685	14691	14643	14929	14865	14890	14791	14755	14753	14903	14925	14770	14903	133
COVID															
Substantive	0	0	28	41	10	6	12	9	8	8	13	76	9	13	5
Bank	97	94	64	47	35	19	31	59	65	99	114	65	87	114	27
Agency	17	13	23	24	10	22	30	40	63	52	60	65	66	60	-6
Sub-total	113	107	116	112	55	47	73	108	136	159	188	206	161	188	27
Restoration and recovery															
Substantive	0	0	0	0	0	0	20	18	18	10	10	13	12	10	-2
Bank	0	0	0	0	0	0	16	7	12	1	2	13	2	2	0
Agency	0	0	0	0	0	0	0	2	4	11	11	14	11	11	0
Sub-total	0	0	0	0	0	0	36	27	33	22	23	40	25	23	-2
Winter pressures															
Substantive	0	0	0	0	0	0	0	15	17	21	20	18	18	20	2
Bank	0	0	0	0	0	0	1	23	41	44	80	80	80	80	0
Agency	0	0	0	0	0	0	5	10	19	17	45	44	43	45	1
Sub-total	0	0	0	0	0	0	7	49	78	82	145	143	142	145	3
CIP savings															
Substantive	0	0	0	0	0	0	-7	-7	-11	-9	-10	-8	-10	-10	0
Bank	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Agency	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Sub-total	0	0	0	0	0	0	-7	-7	-11	-9	-10	-8	-10	-10	0
Total forecast															
Substantive	13921	13948	13909	13907	13918	13853	13855	13850	13894	13870	13989	14062	13894	13989	95
Bank	661	598	577	681	748	729	795	734	708	717	796	760	732	796	65
Agency	241	245	321	167	319	329	347	382	388	420	464	483	462	464	1
Total	14823	14791	14807	14755	14985	14912	14998	14966	14990	15007	15249	15305	15088	15249	160

Appendix 5: update on CIP (M7-M12) (1/2)

Planned	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	1,082	1,029	1,044	1,509	1,256	2,077	7,998	8,304
Non Cash Releasing / Clinical Productivity	24	19	14	19	19	19	115	167
Total All	1,106	1,048	1,059	1,528	1,275	2,096	8,112	8,471






Actual / Forecast	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	685	1,333	1,217	1,942	1,979	2,126	9,284	9,591
Non Cash Releasing / Clinical Productivity	363	282	290	290	255	180	1,660	1,734
Total All	1,049	1,616	1,507	2,232	2,233	2,306	10,943	11,325

Actual / Forecast (Risk Adjusted)	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	685	1,333	1,217	1,942	1,979	1,320	8,477	8,784
Non Cash Releasing / Clinical Productivity	363	282	290	290	255	177	1,657	1,732
Total All	1,049	1,616	1,507	2,232	2,233	1,497	10,134	10,516

The risk adjusted schemes figures are valued in the above table at 100% (Green), 25% (Amber) and 0% (Red)

Variance to Plan (Risk Adjusted)	20/21 Months 7-12 £'000							Total FY £'000
	Oct	Nov	Dec	Jan	Feb	Mar	Total	
Cash releasing saving - Oct 20 to Mar 21	(397)	304	173	434	723	(757)	479	480
Non Cash Releasing / Clinical Productivity	339	264	276	271	235	158	1,543	1,565
Total All	(57)	568	448	705	958	(599)	2,022	2,045

Appendix 5: update on CIP (2/2)



Appendix 6: activity and SLA income

Point of delivery	FY19/20 YTD (M7-12)		Activity YTD (M7-12)			Income YTD £000 (M7-12)			Income forecast £000 (M7-12)		
	Activity	Income £000	Plan	Actual	Variance	Plan	Actual	Variance	Previous Month Forecast	Potential outturn	Variance
Emergency department	107,164	16,800	99,665	75,547	(24,118)	16,596	12,514	(4,083)	16,681	15,922	(759)
Day cases	44,977	26,182	36,081	32,465	(3,616)	22,289	17,361	(4,928)	21,343	20,561	(781)
Elective	7,944	32,730	6,459	4,865	(1,594)	28,305	19,165	(9,140)	25,355	23,478	(1,877)
Non elective	51,307	112,897	48,412	43,298	(5,115)	112,416	96,369	(16,046)	119,958	117,411	(2,548)
Outpatient – first	109,511	21,055	100,028	77,620	(22,408)	19,550	12,828	(6,722)	16,785	15,992	(792)
Outpatient – follow up	262,620	22,350	237,425	232,851	(4,574)	21,838	14,907	(6,931)	19,728	18,678	(1,051)
Outpatient procedures	67,841	9,636	52,257	43,240	(9,017)	8,118	6,878	(1,240)	8,076	8,054	(22)
Critical care services	25,680	25,889	22,992	20,803	(2,189)	23,665	21,061	(2,604)	25,482	25,458	(24)
Renal dialysis and transplant	80,565	13,242	79,422	79,358	(64)	12,840	12,319	(521)	15,125	14,934	(191)
Other central SLA income	3,504,028	57,971	3,472,708	3,184,594	(288,114)	85,375	134,775	49,399	141,108	155,743	14,634
Excluded devices & Medicines	15,686	42,945	-	15,444	15,444	40,277	49,025	8,749	60,239	59,385	(853)
Total SLA income (before fines)	4,277,323	381,697	4,155,447	3,810,084	(345,363)	391,269	397,203	5,934	469,879	475,614	5,735
Fines and penalties	-	(357)	-	-	-	-	-	-	-	-	-
Total SLA income (after fines)	4,277,323	381,340	4,155,447	3,810,084	(345,363)	391,269	397,203	5,934	469,879	475,614	5,735

As a result of the interim financial arrangements in place during COVID, all NHS providers are paid a block payment from commissioners at values set nationally by NHSE/I. The Trust has aligned its patient care income plan with these block payments, although there are still some variances to the plan which are due to variable elements within the block contract and patient care income which is not included within the block amount.

Although income is blocked, the Trust continues to report significant reductions in activity due to COVID.

Elective services are continuing to see the impact of Covid-19, with Critical Care services being impacted to a lesser degree. Renal Dialysis and Transplant is the only service with activity in line with last year's performance.

Appendix 7: financial performance by CMG and directorate (1/2)

	Trust overall					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	528,106	526,499	(1,607)	630,692	635,252	4,560
Total Pay	(303,735)	(303,072)	663	(365,352)	(366,136)	(784)
Non Pay	(164,764)	(162,511)	2,253	(215,194)	(210,003)	5,192
Total Expenditure	(468,499)	(465,584)	2,916	(580,546)	(576,139)	4,407
EBITDA	59,607	60,915	1,308	50,146	59,113	8,967
Non Operating Costs	(22,089)	(21,999)	91	(25,830)	(27,379)	(1,549)
Donated Assets	(2,708)	(3,231)	(523)	(6,120)	(4,790)	1,330
Net Surplus/(Deficit)	34,810	35,685	876	18,196	26,944	8,747

	CHUGGS					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	81,820	81,119	(701)	98,334	97,798	(536)
Total Pay	(27,498)	(27,453)	46	(33,107)	(32,980)	127
Non Pay	(31,437)	(30,982)	455	(37,915)	(37,505)	410
Total Expenditure	(58,935)	(58,435)	500	(71,022)	(70,485)	537
EBITDA	22,885	22,684	(201)	27,312	27,313	1

	CSI					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	28,258	28,384	126	34,137	34,478	341
Total Pay	(42,239)	(42,082)	157	(50,992)	(50,911)	81
Non Pay	(5,793)	(5,495)	298	(7,187)	(8,180)	(994)
Total Expenditure	(48,032)	(47,577)	455	(58,179)	(59,092)	(913)
EBITDA	(19,774)	(19,193)	581	(24,042)	(24,613)	(572)

	ESM					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	88,369	88,591	222	105,793	106,040	247
Total Pay	(50,586)	(50,348)	238	(60,979)	(60,664)	315
Non Pay	(19,976)	(19,952)	23	(23,941)	(24,083)	(142)
Total Expenditure	(70,561)	(70,301)	261	(84,920)	(84,747)	173
EBITDA	17,808	18,290	482	20,873	21,293	420

	ITAPS					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	17,623	17,648	26	21,044	21,070	26
Total Pay	(32,873)	(32,918)	(45)	(40,160)	(40,205)	(45)
Non Pay	(9,265)	(9,186)	79	(11,156)	(11,277)	(121)
Total Expenditure	(42,138)	(42,104)	34	(51,316)	(51,482)	(166)
EBITDA	(24,515)	(24,456)	60	(30,272)	(30,413)	(140)

	MSS					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	48,934	48,908	(25)	58,646	58,596	(50)
Total Pay	(24,114)	(23,992)	121	(29,121)	(28,789)	332
Non Pay	(8,485)	(7,983)	502	(10,416)	(9,884)	532
Total Expenditure	(32,598)	(31,975)	623	(39,537)	(38,673)	864
EBITDA	16,335	16,933	598	19,110	19,923	814

Appendix 7: financial performance by CMG and directorate (2/2)

	RRCV					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	89,353	89,225	(129)	107,186	107,239	53
Total Pay	(36,741)	(36,896)	(155)	(44,226)	(44,480)	(254)
Non Pay	(25,303)	(25,108)	194	(30,255)	(30,335)	(80)
Total Expenditure	(62,044)	(62,005)	39	(74,481)	(74,815)	(334)
EBITDA	27,310	27,220	(90)	32,705	32,424	(281)

	W&C					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	76,416	76,467	51	91,703	91,888	185
Total Pay	(40,157)	(40,174)	(17)	(48,210)	(48,217)	(7)
Non Pay	(16,489)	(16,567)	(78)	(19,859)	(20,493)	(634)
Total Expenditure	(56,646)	(56,741)	(95)	(68,068)	(68,710)	(641)
EBITDA	19,770	19,726	(44)	23,634	23,178	(456)

	Estates and facilities					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	6,245	6,257	12	7,382	7,499	117
Total Pay	(17,317)	(17,349)	(32)	(20,812)	(20,844)	(32)
Non Pay	(15,238)	(14,978)	260	(18,369)	(18,048)	321
Total Expenditure	(32,555)	(32,327)	228	(39,181)	(38,892)	289
EBITDA	(26,310)	(26,070)	240	(31,799)	(31,393)	406

	Corporate					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	6,312	6,260	(52)	7,507	10,375	2,868
Total Pay	(17,159)	(17,177)	(18)	(20,512)	(20,724)	(212)
Non Pay	(20,962)	(21,171)	(210)	(25,929)	(26,301)	(372)
Total Expenditure	(38,120)	(38,348)	(228)	(46,441)	(47,025)	(584)
EBITDA	(31,809)	(32,089)	(280)	(38,934)	(36,650)	2,284

	R&I					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	15,778	15,523	(255)	19,069	18,560	(509)
Total Pay	(6,452)	(6,466)	(14)	(7,744)	(7,760)	(16)
Non Pay	(7,855)	(8,036)	(182)	(9,432)	(9,454)	(22)
Total Expenditure	(14,307)	(14,502)	(195)	(17,176)	(17,214)	(38)
EBITDA	1,471	1,021	(450)	1,893	1,346	(547)

	Alliance					
	YTD			Full year forecast		
	Forecast	Actual	Variance	Forecast (M10)	Potential Outturn (M11)	Variance
	£000	£000	£000	£000	£000	£000
Total Income	9,043	9,091	48	10,894	10,952	57
Total Pay	(4,935)	(4,826)	109	(5,895)	(5,786)	109
Non Pay	(3,595)	(3,533)	62	(4,390)	(4,329)	62
Total Expenditure	(8,529)	(8,359)	170	(10,285)	(10,115)	170
EBITDA	513	732	218	609	837	228

Appendix 8: statement of financial position

£000	Balance at 31 March 2020	Current month			Forecast outturn
		31-Jan-21	28-Feb-21	Movement	Forecast
Non current assets					
Intangible assets	6,570	4,441	4,622	182	4,425
Property, plant and equipment	529,798	540,279	544,774	4,495	565,874
Other non-current assets	2,533	1,663	1,959	296	2,134
Total non-current assets	538,901	546,383	551,356	4,973	572,433
Current assets					
Inventories	21,941	21,498	21,806	307	21,364
Trade and other receivables	52,156	60,173	52,803	(7,370)	46,794
Cash and cash equivalents	16,016	132,141	145,542	13,401	90,859
Total current assets	90,113	213,812	220,151	6,338	159,017
Current liabilities					
Trade and other payables	(59,637)	(90,174)	(88,720)	1,455	(121,262)
Borrowings / leases	(339,814)	(1,093)	(1,093)	0	(1,093)
Accruals	(23,996)	(12,312)	(10,580)	1,732	(14,233)
Deferred income	(7,571)	(89,086)	(93,968)	(4,883)	(7,600)
Provisions < 1 year	(6,709)	(5,806)	(5,810)	(3)	(3,354)
Total current liabilities	(437,727)	(198,472)	(200,170)	(1,699)	(147,542)
Net current assets / (liabilities)	(347,615)	15,341	19,980	4,639	11,475
Non-current liabilities					
Borrowings / leases	(20,675)	(4,152)	(5,570)	(1,418)	(3,313)
Provisions for liabilities & charges	(7,041)	(6,045)	(6,045)	0	(16,755)
Total non-current liabilities	(27,716)	(10,197)	(11,615)	(1,418)	(20,068)
Total assets employed	163,570	551,527	559,721	8,195	563,840
Total taxpayers equity					
Public dividend capital	369,325	722,871	722,871	0	742,696
Revaluation reserve	168,342	168,342	168,342	0	168,342
Income and expenditure reserve	(374,098)	(339,687)	(331,492)	8,194	(347,198)
Total taxpayers equity	163,570	551,526	559,721	8,194	563,840


The Statement of Financial Position (SOFP) for February and movements from the previous month are presented in the table opposite, together with a M12 forecast outturn.

The key in month movements were as follows:

- **Non Current Assets**
 - PPE And Intangibles increased in value by £4.7m, as an acceleration of capital programme spend in February (£7.2m) was partially offset by in month depreciation and amortisation costs incurred (£2.5m)
- **Working Capital**
 - **Trade and other Receivables** - reduced by £7.4m in month, mainly as a consequence of the timing of prepayments, in particular CNST premium, which is paid in 10 monthly installments (£5.7m), receipt of charity income (£3.1m), VAT claims (£3m) and hosted research & development NHIR funds (£2m), offset by the invoicing of the learning and development contract for February to March period to HEE (£7.9m).
 - **Cash Balances** - increased by £13.4m, mainly as a result of the increase in cash receipts highlighted above. The cash forecast is currently being reviewed to align to the income and expenditure forecast.
 - **Trade and other payables and accruals** - reduced by £3.2m mainly as a result of the timing of payments transacted through the purchase ledger, in that a higher value of payments were processed in M11 compared with M10, which were either pending payment or had been accrued at the end of M10 (£4.1m), offset by the accrual of the M11 PDC dividend (£1m).
 - **Deferred Income balances** - Increased by £4.9m mainly due to deferment of education and training LDA funding for March (refer to receivables above).
- **Non Current Liabilities**
 - Borrowings increased by £1.4m, in relation to capital additions (principle) associated with Althea MES contract, in line with the agreed contract model.
- **Reserves**
 - The cumulative deficit on the I&E reserve reduced by the in month surplus of £8.2m generated in February.

Appendix 9: cashflow forecast

Monthly cash flow £000	Annual	Actual YTD											Forecast
		Apr	May	June	July	Aug	Sept	Oct	Nov	Dec	Jan	Feb	Mar
Receipts													
SLA block payments	934,231	155,510	77,843	77,767	77,755	77,755	77,755	77,304	77,374	73,257	80,512	81,399	0
COVID-19 top up	149,605	20,555	13,592	12,539	10,263	10,263	10,263	0	17,202	13,732	13,732	13,732	13,732
SLA performance (for prior years)	0	0	0	0	0	0	0	0	0	0	0	0	0
Health education payments	44,372	11,004	0	0	3,389	0	2,830	6,365	0	12,807	0	0	7,976
Other NHS income	67,033	10,836	6,080	7,801	2,697	3,512	3,383	3,518	5,947	3,986	2,898	5,305	11,070
PDC - capital	371,893	0	0	0	0	349,586	1,095	0	0	2,000	0	0	19,212
TMP	39,357	3,470	3,131	2,486	3,185	3,284	2,726	3,299	3,906	3,660	3,140	3,727	3,343
Other non-NHS income	76,420	3,827	4,958	3,169	5,575	6,156	2,654	4,793	2,428	5,187	2,828	10,340	24,506
Total receipts	1,682,910	205,202	105,605	103,761	102,863	450,555	100,706	95,280	106,857	114,629	103,110	114,503	79,839
Salaries and wages	(698,236)	(55,409)	(57,033)	(57,778)	(57,742)	(57,466)	(57,549)	(57,885)	(57,059)	(58,668)	(58,271)	(58,347)	(65,028)
Creditor payments	(508,466)	(40,514)	(48,915)	(37,921)	(46,666)	(39,999)	(40,827)	(36,007)	(42,992)	(43,505)	(38,399)	(39,277)	(53,444)
NHS creditors	0	0	0	0	0	0	0	0	0	0	0	0	0
PDC dividend	(12,699)	0	0	0	0	0	0	0	(1,949)	0	0	0	(10,750)
Repayment of loans	(349,586)	0	0	0	0	(349,586)	0	0	0	0	0	0	0
TMP	(37,918)	(4,265)	(2,445)	(2,322)	(3,353)	(2,876)	(2,539)	(3,692)	(3,736)	(4,284)	(2,861)	(2,132)	(3,413)
Total payments	(1,568,987)	(100,188)	(108,393)	(98,021)	(107,761)	(449,928)	(100,916)	(97,584)	(105,736)	(106,457)	(99,531)	(99,756)	(132,636)
Month end balance	113,923	105,014	(2,788)	5,740	(4,898)	627	(210)	(2,304)	1,121	8,172	3,579	14,747	(52,797)
Cash in transit and cash in hand adjustment	(1,161)	235	138	(328)	(124)	95	60	(71)	0	0	2,066	(1,346)	(1,886)
Balance brought forward	16,016	16,016	121,265	118,614	124,027	119,005	119,727	119,577	117,202	118,324	126,496	132,141	145,542
Balance carried forward	90,859	121,265	118,614	124,027	119,005	119,727	119,577	117,202	118,324	126,496	132,141	145,542	90,859
Planned balance c/f													
Month end cash balance	90,859	121,265	118,614	124,027	119,005	119,727	119,577	117,202	118,324	126,496	132,141	145,542	90,859



Cash balances increased by £13.4m to £145.6m at the end of February, driven by income receipts of £114.5m less payments of £99.8m (refer previous slide).

SLA cash receipts include monthly advance payments of the 2020/21 block income, which ended in February, such that no SLA income will be paid in March (which represents the 'catch up' month). As a result, year end cash balances are forecast to reduce to £90.9m by 31 March 2021, although the Trust's underlying cash position is significantly lower than this, due to the acceleration of the capital commitments in March, which will not be expended in cash terms until Q1 in 2021/22. Further work is being undertaken to fully understand the level of cash payments that will effectively be deferred to 2021/22, as part of the development of the cash plan for Q1.

Appendix 10: working capital (1/2)

	Mar-20	Q1 YTD	Q2 YTD	Q3 YTD	Month 11 YTD
Debtor and creditor days					
Debtor days	18	9	12	20	17
Creditor days	75	88	84	91	97

BPCC (cumulative)					
Value %	67%	92%	92%	93%	92%
Volume %	47%	92%	91%	89%	90%

BPCC (SMEs) paid within 30 days					
Value %	13%	92%	84%	90%	91%
Volume %	7%	93%	87%	86%	86%

BPCC (SMEs) paid within 5 days					
Value %	13%	24%	20%	59%	56%
Volume %	7%	28%	26%	24%	20%

BPPC

Performance has been broadly maintained across the year. Procure to pay financial improvement grip and control actions will be taken over the next 6 months to improve the performance up towards the 95% target. A purchase to pay working group has been re-established to oversee the implementation of these actions.

We have maintained our performance to SME suppliers from the prior month and are continuing to implement improvements to processes for these suppliers to support performance against the 5 day payment target, as part of the financial improvement plan.

Appendix 10: working capital (2/2)

	0 to 30 days	31 to 60 days	61 to 90 days	Over 90 days	Percentage over 90 days
February 2020	£000	£000	£000	£000	%
Non-NHS receivables	2,484	1,372	127	3,922	50%
NHS receivables	9,733	1,373	159	403	3%
Total receivables	12,217	2,745	286	4,324	22%
Bad debt provision					
Non-NHS payables	19,013	1,933	1,824	936	4%
NHS payables	2,544	1,411	579	2,862	39%
Total payables	21,557	3,344	2,403	3,798	12%

January 2020					
Non-NHS receivables	2,957	541	318	4,172	52%
NHS receivables	3,813	381	82	852	17%
Total receivables	6,770	921	400	5,024	38%
Bad debt provision					
Non-NHS payables	14,266	4,807	1,192	1,963	9%
NHS payables	1,579	738	261	4,807	65%
Total payables	15,845	5,545	1,453	6,770	23%

Aged Debt (Sales Ledger)

Overall sales ledger debt increased by £6.5m to £19.6m, mainly associated with the invoicing of the learning and development contract for February to March period to HEE. Over 90 days debt reduced by £700k in M11, mainly as a result of settlement by Leicester Partnership Trust of final year end services charges in respect of 2019/20 financial year. (£0.4m)

It should be noted that £0.6m of the over 90 debt is currently on an instalment repayment plans, with 60% of outstanding over 90 days debt relating to overseas and private patients debt. A workstream has commenced and additional resources allocated to retrospectively recover and strengthen processes to ensure effective recovery of overseas and private patient debt going forward, as part of the Financial Improvement Plan. It should be recognised that 75% of all overseas debt since 2015 has been underwritten by commissioners, in the event that debts are not recovered from the debtor, in line with national guidance, although clearly it is essential that every effort is made to pursue and recover these outstanding debts at source to reduce the adverse impact on available ICS funding.

All other categories of aged debt are subject to application of appropriate debt collection protocols and escalation processes. An exercise is also being undertaken during the last quarter to identify debts for potential write off.

Appendix 11: capital programme

Capital scheme	YTD £000			Full year £000
	Plan	Actual	Variance	M11 Forecast
Reconfiguration Scheme	3,240	2,637	(603)	3,616
ICU	7,235	6,267	(968)	7,893
EMCHC	10,622	9,234	(1,388)	11,723
Other reconfiguration schemes	757	4	(753)	553
MEE 3T MRI Scanner	3,177	3,177	0	3,177
Medical Equipment	2,018	1,293	(725)	3,723
MES Replacement	300	76	(224)	316
MES Enabling Costs of MES	411	194	(217)	711
Additional medical equipment b/fwd	0	0	0	1,322
CentriMag Trolley System x 3		0	0	180
Spectrophotometer	0	0	0	8
IM&T Infrastructure programme	2,285	1,467	(818)	1,991
IM&T eHospital	1,199	1,304	105	1,056
IM&T General	0	393	393	596
Digital Aspirant programme	0	333	333	501
HSLI	0	1,111	1,111	1,673
Cyber resilience	0	63	63	95
Additional IT related Covid-19 spend	0	389	389	586
LIMS system	0	357	357	537
Ipads videoconferencing	0	13	13	19
Covid IT	0	42	42	63
Critical Infrastructure Risk (CIR)	2,531	2,550	19	4,263
Slippage / Backlog / Other	1,904	2,313	409	2,469
Linear Accelerator Bunker	100	129	29	164
Linear Accelerator + CT	0	0	0	0
Maternity Theatre Refurbishment	0	0	0	0
E&F Breakdown fund - defined schemes	950	0	(950)	1,052
Backlog maintenance	128	23	(105)	600
Hope Expansion Project	634	678	44	720
Slippage - Diagnostics Endoscopy	0	0	0	0
E&F CAT3 Lab Sandringham	60	9	(51)	44
ED Scheme	999	392	(607)	1,649
Vaccination Hub	0	0	0	772
Car parking scheme ANPR	0	0	0	400
Covid-19 Schemes	5,225	5,165	(60)	5,225
Covid-19 Critical care wards	35	177	142	1,270
Covid-19 Endoscopy Scheme	1,229	1,670	441	3,233
Other Covid-19 related items	0	26	26	1,015
eQuip	2,427	1,783	(644)	2,000
Other - donated	356	1,121	765	770
Other items	459	548	89	2,096
Brokerage	0	0	0	3,000
Total	48,281	44,938	(3,343)	71,081

Impact of Covid delaying schemes

The impact of Covid on capital schemes has been assessed and built into the forecast outturn.

Funding opportunities and issues

The Trust has received approved Covid-19 PDC funding of £3.9m. The remainder of the total Covid-19 related spend will be met through internal funding.

The Trust has received a total of £21.9m of PDC funding.

Impact on the future capital programme

The YTD underspend is £3.3m and the potential full year underspend is £3.4m against the revised capital plan (including £3m of potential brokerage). The Trust still needs to spend £23.1m of capital in March to achieve this forecast position.

The Capital Finance team have worked with scheme leads and capital sub groups to produce the forecast and obtain assurances that items will be ordered and delivered by the year end to ensure the expenditure can be included in the current year capital limits. Any slippage will be subject to consideration in the 2021/22 capital programme.

The separate capital paper on the agenda outlines actions that we are planning to take to strengthen capital reporting processes in 2021/22.

Funding source		£000
A	Internally generated funds	32,453
B	Use of surplus	5,103
C	COVID-19	3,912
D	Finance lease	7,068
E	Other	22,545
Total		71,081

Appendix 12

UHL - Total Actual WTEs Jan-19 to Jan-21

By Staff Group

Staff Group	Jan-19					Jan-21					Total Movem't	Total Movem't %
	ESR Contracted	Bank	Overtime	Agency	Total Actual	ESR Contracted	Bank	Overtime	Agency	Total Actual		
	WTE	WTE	WTE	WTE	WTE	WTE	WTE	WTE	WTE	WTE		
Consultants	807	0	0	9	817	859	0	0	14	873	57	7.0%
Other medical	1,179	0	0	35	1,214	1,272	1	1	16	1,289	75	6.2%
Medical Total	1,986	0	1	44	2,031	2,131	1	1	30	2,163	132	6.5%
Qualified nursing	3,637	219	56	108	4,021	3,939	223	70	57	4,290	269	6.7%
Support to nursing staff	1,654	208	17	92	1,971	1,730	219	28	101	2,077	105	5.3%
Nursing & midwifery Total	5,291	427	74	200	5,992	5,669	442	98	158	6,366	374	6.2%
Allied Health Professionals	677	9	5	20	711	690	8	6	37	741	31	4.3%
Healthcare Scientists	456	11	7	24	497	478	15	6	2	500	3	0.6%
Other Scientific & Technical	454	3	9	2	468	505	5	6	1	518	49	10.5%
Other support to clinical staff	647	19	4	0	670	732	10	5	0	747	77	11.6%
Other clinical Total	2,234	43	25	45	2,346	2,406	38	22	40	2,507	161	6.8%
Admin & estates staff	2,595	84	26	2	2,707	2,585	76	18	13	2,692	-15	-0.5%
Managers & senior managers	270	1	0	1	272	261	1	0	0	262	-10	-3.6%
Other Infrastructure & Support Staff	1,145	113	42	6	1,306	1,108	113	55	99	1,375	68	5.2%
Non - clinical Total	4,009	199	68	9	4,285	3,953	190	73	113	4,329	44	1.0%
Total	13,520	669	167	298	14,654	14,159	671	194	341	15,365	711	4.8%

ESR Contracted WTE = total contracted WTEs on ESR at end of month + / - internal & external recharges

Bank WTE & Overtime WTE = calculated WTEs from hours worked per ESR payroll data

Agency WTE = as calculated based on spend in month

As requested by the Finance and Investment Committee, the table above identifies the workforce increase of the Trust during the two year period to January 2021. The actual workforce increase over the period was 711 wte's (4.8%), with the majority of this seen in nursing and midwifery, and medical staff.

The increase in wte's has been mainly in the following CMGs:

- ESM 205 (Medical and Nursing staff of 198.5 wte's, reflecting the opening of additional/winter capacity, and other approved investments)
- RRCV 132 (Nursing and medical staff of 107 wte's, reflecting safe staffing levels, winter capacity, and other approved investments)
- W&C 81 (Nursing and medical staff of 69.9 wte's, reflecting safe staffing levels, and other approved investments)
- CSI 108 (Pharmacists, AHP and support staff of 106.5 wte's, reflecting safe staffing levels, winter capacity, and other approved investments)

The above reflects the approval of significant investments in 2019/20, with a full year effect net cost of £15m, as identified in the review of the Trust's underlying financial position. Since 2020/21 investments have been reviewed by the Financial Recovery Board, aligned to key risks via the completion of quality impact assessments.